Concordia UK

What Concordia UK does

ADVANZ PHARMA is a global pharmaceutical company headquartered in London, UK, that develops, in-licenses, and commercialises specialty, hospital, and rare disease medicines across a broad range of therapeutic areas including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The company's portfolio strategy combines acquired originator brands, specialty generics, and a rapidly expanding biosimilars pipeline, with recent additions including territory rights to Progynova and Cyclo-Progynova in selected EMEA countries and global rights to Ilomedin.

The commercial model is built around being a partner of choice for innovative biopharma and pharmaceutical development companies seeking global commercialisation capabilities. ADVANZ PHARMA maintains direct commercial presence in more than 20 countries and reaches more than 90 countries through an established partner network of more than 300 organisations engaged in production, development, portfolio licensing, and commercialisation. A Centre of Excellence in Mumbai, India supports global operations, and the company's core biosimilars franchise is co-developed with Alvotech, including Gobivaz (a biosimilar to Simponi/golimumab) and a developing Eylea biosimilar.

The company is currently undertaking a formal sale process. Revenue generation is driven primarily by pharmaceutical product sales across the specialty, hospital, and rare disease portfolio, distributed globally through direct sales infrastructure in 20+ markets and partner-led distribution across the broader 90+ country footprint. Pricing for pharmaceutical products is not publicly disclosed.

Name

Concordia UK

Legal name

ADVANZ PHARMA Corp. Limited

Website

https://concordiarx.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

ADVANZ PHARMA is a London-headquartered global pharmaceutical company that commercialises specialty, hospital, and rare disease medicines across 90+ countries, with a portfolio spanning biosimilars, specialty generics, and originator brands in partnership with over 300 biopharma collaborators.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Generic pharmaceuticals
• Pharmaceutical licensing
• Generic medicines
• Pharmaceutical marketing
• Specialty pharmaceuticals

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical Product Sales: ADVANZ PHARMA generates revenue through the sale of innovative medicines, specialty generics, biosimilars, and originator brands. The company focuses on specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases.

Distribution channels3 records

Marketing channels3 records

Core offering

Concordia UK develops, licenses, and markets generic pharmaceutical products. Founded in 2002 and headquartered in London, UK, the company is a privately-held, for-profit pharmaceutical firm with 11–50 employees focused on the development, licensing, and commercialization of generic medications.

Product overview

ADVANZ PHARMA operates as a global pharmaceutical company offering a diversified portfolio comprising innovative medicines, specialty generics, and originator brands, with a rapidly expanding biosimilars pipeline. The company focuses on specialty, hospital, and rare disease medicines spanning therapeutic areas including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and rare diseases. The portfolio strategy combines acquired brands (Progynova®, Cyclo-Progynova®, Ilomedin®) with internally developed biosimilars developed in partnership with Alvotech (Gobivaz®, Eylea® biosimilar). The company commercialises products in over 90 countries globally with direct commercial presence in more than 20 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic pharmaceutical products Generic pharmaceutical products developed, licensed, and marketed by Concordia UK. The portfolio targets healthcare buyers such as hospitals, pharmacies, and wholesalers needing cost-effective generic formulations.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• AlvotechcoreStrategic or Co-development Partner · 30 January 2026ADVANZ PHARMA partnered with Alvotech to develop and commercialize biosimilar products. The partnership has resulted in marketing approvals for Gobivaz (biosimilar to Simponi/golimumab) across the European Economic Area and from the MHRA. A patent settlement was also secured for the Eylea biosimilar, establishing a pathway to market.
• Biopharmaceutical Development CompaniescoreStrategic or Co-development PartnerADVANZ PHARMA partners with innovative biopharma and pharmaceutical development companies to bring specialty, hospital, and rare disease medicines to patients worldwide. The company works with over 300 partners in production, development, portfolio licensing, and commercialization to broaden patient access and improve health outcomes.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Sandoz (Novartis): Sandoz is the global leader in generics and biosimilars with strong European hospital/specialty positioning. Directly comparable business model combining generics, biosimilars, and specialty medicines sold across multiple geographies.
• Viatris: Viatris is a global healthcare company formed from Mylan and Upjohn, operating across generics, specialty, and biosimilars worldwide. Highly comparable diversified pharma model with similar geographic breadth and channel partner networks.
• Hikma Pharmaceuticals: Hikma is a UK-headquartered specialty generics and hospital-focused pharmaceutical company. Directly comparable given shared London base, hospital/specialty focus, MENA and European distribution, and biosimilar pipeline.
• Mallinckrodt Pharmaceuticals: Mallinckrodt focuses on specialty, hospital, and rare disease medicines including branded and specialty generics. Directly comparable therapeutic-area mix and hospital channel distribution model.
• Endo International: Endo operates a specialty generics and branded specialty pharmaceutical business with significant hospital presence. Comparable specialty/hospital focus, though concentrated more in North America than ADVANZ's EMEA-centric footprint.
• Amneal Pharmaceuticals: Amneal is a US-based affordable medicines company operating across generics, specialty, and biosimilars. Comparable diversified pharma model with growing biosimilar pipeline and global ambitions.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic medicines producer with significant specialty and biosimilar operations. Comparable across generics, specialty, and biosimilars, but materially larger and broader in scope than ADVANZ.
• Stada Arzneimittel: Stada is a European-focused generics and specialty pharma company with biosimilar ambitions. Comparable European specialty/generic footprint though broader consumer healthcare presence than ADVANZ.

Emerging players

• Alvotech: Alvotech is a pure-play biosimilar developer that is ADVANZ's strategic development and commercialization partner (e.g., Gobivaz, Eylea biosimilar). Partly a partner and partly a peer in the biosimilar pipeline space.
• Lupin Pharmaceuticals: Lupin is an India-headquartered global generic and specialty pharmaceutical company with growing complex generics and biosimilar pipelines. Comparable emerging-player model with growing European/US specialty focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/advanz-pharma/about
• Xx.com/concordiaintl

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concordia UK